Clinical Trial Update: Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lazertinib in NSCLC patients with uncommon EGFR mutations is ongoing with status not yet determined.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Lazertinib (lazertinib)

Snippet

Sponsor: Yonsei University | Conditions: NSCLC | Phase 2 | Status: UNKNOWN